By Gilang Cahya 
In a groundbreaking discovery, researchers at University College London (UCL) and University Medical Center Utrecht have identified a sophisticated mechanism by which bowel cancer cells strategically regulate their growth and survival through the precise control of genetic mutations. This phenomenon, previously unobserved, reveals that cancer cells do not simply accumulate genetic errors by chance but actively engage in an "evolutionary balancing act," employing genetic on-off switches to maximize their potential for progression and evasion of the body’s defenses. The findings, published in the prestigious journal Nature Genetics, offer profound implications for personalized cancer medicine and our understanding of tumor evolution.
Unveiling the "Genetic Switch" in Cancer Progression
For decades, the prevailing understanding of cancer was that the sheer number of genetic mutations within a tumor was a consequence of random chance. However, this new research challenges that notion, demonstrating a remarkable level of cellular strategy. The study pinpoints mutations in specific DNA repair genes as the key players in this process. These mutations, the researchers found, can be both intentionally created and subsequently repaired, acting as sophisticated "genetic switches."
These switches allow cancer cells to dynamically adjust their mutation rate. When beneficial for rapid growth and overcoming cellular safeguards, the brakes on DNA repair are effectively released, leading to an accelerated accumulation of mutations. Conversely, when a high mutation load becomes detrimental, perhaps by attracting the attention of the immune system, the cancer can flip the switch back, restoring DNA repair mechanisms to protect critical genes and reduce its visibility to immune surveillance.
Dr. Marnix Jansen, a senior author of the study from UCL Cancer Institute and UCLH, explained the intricate strategy: "Cancer cells need to acquire certain mutations to circumvent mechanisms that preserve our genetic code. But if a cancer cell acquires too many mutations, it is more likely to attract the attention of the immune system, because it’s so different from a normal cell. We predicted that understanding how tumours exploit faulty DNA repair to drive tumour growth — whilst simultaneously avoiding immune detection — might help explain why the immune system sometimes fails to control cancer development."
The Evolutionary Tightrope: Balancing Growth and Evasion
The research team meticulously analyzed whole genome sequences from 217 mismatch repair deficient (MMRd) bowel cancer samples, part of the UK’s 100,000 Genomes Project. Their investigation focused on identifying correlations between the total number of mutations within a tumor and alterations in key DNA repair genes. This detailed examination led to the identification of a significant link between mutations in the MSH3 and MSH6 genes and an exceptionally high overall mutation burden.
To validate their hypothesis, the researchers employed advanced organoid models – complex, three-dimensional cell cultures derived from patient tumor samples. These laboratory-grown tumors allowed for precise observation and manipulation, confirming that "flip-flop" mutations within DNA repair genes indeed function as switches, controlling the rate at which new mutations arise.
Dr. Suzanne van der Horst from University Medical Center Utrecht elaborated on this critical finding: "Our study reveals that DNA repair mutations in the MSH3 and MSH6 genes act as a genetic switch that cancers exploit to navigate an evolutionary balancing act. On one hand, these tumours roll the dice by turning off DNA repair to escape the body’s defence mechanisms. While this unrestrained mutation rate kills many cancer cells, it also produces a few ‘winners’ that fuel tumour development."
The adaptive nature of these switches is particularly striking. "The really interesting finding from our research is what happens afterwards," Dr. van der Horst continued. "It seems the cancer turns the DNA repair switch back on to protect the parts of the genome that they too need to survive and to avoid attracting the attention of the immune system. This is the first time that we’ve seen a mutation that can be created and repaired over and over again, adding it or deleting it from the cancer’s genetic code as required."
The Role of Repetitive DNA and Bacterial Parallels
The specific DNA repair mutations implicated in this phenomenon occur within repetitive stretches of DNA. These sequences, characterized by the repeated patterns of the DNA bases A, T, C, and G, are known to be prone to copying errors during cell division. When these errors disrupt the function of DNA repair genes, the cell loses its ability to accurately correct mistakes in these repetitive regions, leading to an increased mutation rate.
Dr. Hamzeh Kayhanian, the study’s first author from UCL Cancer Institute and UCLH, highlighted the shift in perspective this discovery represents: "The degree of genetic disarray in a cancer was previously thought to be purely down to chance accumulation of mutations over many years. Our work shows that cancer cells covertly repurpose these repetitive tracts in our DNA as evolutionary switches to fine-tune how rapidly mutations accumulate in tumour cells."
Intriguingly, this evolutionary strategy is not unique to human cancers. The researchers noted striking similarities to mechanisms observed in bacteria, where genetic switches have been identified as key drivers of antibiotic resistance. "Interestingly, this evolutionary mechanism had previously been found as a key driver of bacterial treatment resistance in patients treated with antibiotics," Dr. Kayhanian stated. "Like cancer cells, bacteria have evolved genetic switches which increase mutational fuel when rapid evolution is key, for example when confronted with antibiotics. Our work thus further emphasises similarities between evolution of ancient bacteria and human tumour cells, a major area of active cancer research."
Implications for Personalized Cancer Medicine
The discovery of these adaptive genetic switches has significant implications for the future of cancer treatment, particularly in the realm of personalized medicine. By understanding how a patient’s tumor is manipulating its mutation rate, clinicians could gain a more accurate assessment of its aggressiveness and its potential to evade therapies.
"The researchers say that this knowledge could potentially be used to gauge the characteristics of a patient’s tumour, which may require more intense treatment if DNA repair has been switched off and there is potential for the tumour to adapt more quickly to evade treatment — particularly to immunotherapies, which are designed to target heavily mutated tumours," the original report noted. This implies that tumors exhibiting a switched-off DNA repair mechanism might be more susceptible to certain treatments initially, but also possess a higher capacity for rapid adaptation and resistance development.
Bowel Cancer: A Growing Concern and a New Frontier
Bowel cancer, also known as colorectal cancer, remains a significant health challenge globally. In the UK alone, it is the fourth most common cancer, with approximately 42,900 new cases diagnosed annually. While historically more prevalent in older populations, a concerning trend has emerged in recent decades with a notable increase in cases among individuals under the age of 50. This rise underscores the urgent need for deeper understanding and more effective preventative and therapeutic strategies.
Disruptions in DNA repair mechanisms are a well-established contributor to increased cancer risk. Approximately 20% of bowel cancers, categorized as mismatch repair deficient (MMRd) cancers, are directly linked to mutations in DNA repair genes. While these disruptions facilitate tumor initiation by allowing mutations to accumulate, they also present a double-edged sword. Each accumulating mutation increases the likelihood that the body’s immune system will recognize and target the aberrant cells. This inherent vulnerability is precisely what cancer cells appear to be strategically navigating using the newly identified genetic switches.
Future Directions and Hope for Better Outcomes
The research team is not resting on their laurels. A follow-up study is already underway to investigate the behavior of these DNA repair switches in patients undergoing cancer treatment. This crucial next step aims to understand how these adaptive mechanisms respond to therapeutic interventions and whether they can be exploited to improve treatment efficacy.
Dr. Hugo Snippert, another senior author from University Medical Center Utrecht, expressed optimism for the future: "Overall our research shows that mutation rate is adaptable in tumours and facilitates their quest to obtain optimal evolutionary fitness. New drugs might look to disable this switch to drive effective immune recognition and, hopefully, produce better treatment outcomes for affected patients."
The research was supported by grants from leading organizations including Cancer Research UK, the Rosetrees Trust, and Bowel Research UK. Georgia Sturt, Research and Grants Manager at Bowel Research UK, commented on the significance of the findings: "Cancer’s evasion of immune system destruction is a key element of its ability to grow and spread. Understanding exactly how bowel cancers do this is crucial to optimising treatment for patients. Bowel Research UK are delighted that our funding has contributed to producing this exciting new data, and we look forward to seeing how these discoveries could change treatments for future patients."
This groundbreaking work not only sheds light on the intricate evolutionary strategies employed by cancer cells but also opens promising avenues for developing novel therapeutic approaches. By deciphering and potentially manipulating these genetic switches, scientists and clinicians hope to tip the scales in favor of the patient, leading to more effective treatments and improved survival rates for those battling bowel cancer and potentially other forms of the disease. The ability of cancer cells to orchestrate their own genetic destiny, it appears, is far more sophisticated than previously imagined.